RESUMEN
The fields of coping and emotion regulation have mostly evolved separately over decades, although considerable overlap exists. Despite increasing efforts to unite them from a conceptual standpoint, it remains unclear whether conceptual similarities translate into their measurement. The main objective of this review was to summarize and compare self-reported measures of coping and emotion regulation strategies. The secondary objective was to examine whether other psychological measures (e.g., resilience) indirectly reflect regulatory strategies' effectiveness, thus representing additionally informative approaches. Results indicated substantial overlap between coping and emotion regulation measures. In both frameworks, two to eight individual strategies were usually captured, but only a third included ≤20 items. Most commonly evaluated strategies were reappraisal/reinterpretation, active coping/problem-solving, acceptance, avoidance, and suppression. Evidence also suggested psychological distress and well-being measures, especially in certain contexts like natural stress experiments, and resilience measures are possible indirect assessments of these regulatory strategies' effectiveness. These results are interpreted in the light of a broader, integrative affect regulation framework and a conceptual model connecting coping, emotion regulation, resilience, psychological well-being and psychological distress is introduced. We further discussed the importance of alignment between individuals, contexts, and strategies used, and provide directions for future research. Altogether, coping and emotion regulation measures meaningfully overlap. Joint consideration of both frameworks in future research would widen the repertoire of available measures and orient their selection based on other aspects like length or strategies covered, rather than the framework only.
RESUMEN
Drug-tolerance has emerged as one of the major non-genetic adaptive processes driving resistance to targeted therapy (TT) in non-small cell lung cancer (NSCLC). However, the kinetics and sequence of molecular events governing this adaptive response remain poorly understood. Here, we combine real-time monitoring of the cell-cycle dynamics and single-cell RNA sequencing in a broad panel of oncogenic addiction such as EGFR-, ALK-, BRAF- and KRAS-mutant NSCLC, treated with their corresponding TT. We identify a common path of drug adaptation, which invariably involves alveolar type 1 (AT1) differentiation and Rho-associated protein kinase (ROCK)-mediated cytoskeletal remodeling. We also isolate and characterize a rare population of early escapers, which represent the earliest resistance-initiating cells that emerge in the first hours of treatment from the AT1-like population. A phenotypic drug screen identify farnesyltransferase inhibitors (FTI) such as tipifarnib as the most effective drugs in preventing relapse to TT in vitro and in vivo in several models of oncogenic addiction, which is confirmed by genetic depletion of the farnesyltransferase. These findings pave the way for the development of treatments combining TT and FTI to effectively prevent tumor relapse in oncogene-addicted NSCLC patients.